Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.97), $0.09 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $150.04 million versus the consensus estimate of $139.31 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.